Ask The Pharmacist: Risk Assessment for Opioid Use Disorder (OUD)
February 6, 2024
On December 19, 2023, the U.S. Food and Drug Administration (FDA) approved the first test (AvertD) that uses DNA in assessing whether certain individuals may have an elevated risk of developing opioid use disorder (OUD).
The Value of Maintaining Provider Data Accuracy
January 26, 2024
Coventry understands the value of maintaining accurate provider data; therefore, Coventry is taking aggressive action to ensure network data is current and accurate.
Telephonic Case Manager Delivers Brighter Outcomes for Injured Employee
January 24, 2024
The quick intervention led to faster recovery for the injured employee, beating ODG benchmarks by 24 weeks.
Combined Solution Maximizes Savings
January 24, 2024
Discover how our Physician advisor helped a client save over $15,000 on a single facility bill
Business Insurance Video: Comp Spotlight with Mike Cwynar
January 18, 2024
Mike Cwynar discusses the role of artificial intelligence in workers' compensation.
Ask The Pharmacist: Fixed-Dose Combination Drugs in Workers’ Comp
January 10, 2024
Fixed-dose combination drug products (FDCDPs) are made up of two different drug ingredients in a single formulation, containing a fixed amount of each. Among the more recognizable examples of these are Symbicort (budesonide-formoterol), Suboxone (buprenorphine-naloxone), Treximet (sumatriptan-naproxen), and Tylenol PM (acetaminophen-diphenhydramine). Several FDCDPs for pain management also exist such as Vimovo (naproxen-esomeprazole), Duexis (ibuprofen-famotidine), and Seglentis (celecoxib-tramadol).
Exploring Use of GenAI in P&C
December 6, 2023
Mainstream use of generative AI has prompted claims leaders to explore how the technology can be used to improve claims management. And while GenAI certainly offers tremendous opportunities for the P&C industry, tech leaders must be diligent in ensuring the intricate knowledge and experience in claims management is integrated into these programs.